Among the 20 chronic conditions with the highest impact on the Medicare population, some have no quality measure, which limits Medicare's ability to pay for value.
For many chronic conditions, including many cancer types, there are not effective quality measurements in place, which limits Medicare's ability to pay for value, according to a new assessment from Avalere. Diabetes and chronic renal disease have 21 measures each, but prostate cancer and lung cancer only have 3 measure each.
Both endometrial cancer and Alzheimer's disease, which are among the conditions with the highest impact, currently have no Medicare quality measures, Avalere reported. These high-impact conditions are prioritized based on the relative cost, prevalence, variability, improvability, disease burden, and disparities of each chronic condition to the Medicare popultion.
“As Medicare and other payers move towards value-based payments for services and pharmaceuticals, we need more meaningful quality measures in oncology and selected other areas of medicine to ensure alignment," said Dan Mendelson, Avalere CEO.
Read more at Avalere: http://bit.ly/1fxTaxO
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
High-Risk Care Management Impact on Medicaid ACO Utilization and Spending
July 10th 2025In Massachusetts’ largest Medicaid accountable care organization (ACO), high-risk care management significantly reduced spending, emergency department visits, and hospitalizations, demonstrating that targeted strategies can manage health care costs amid budget constraints.
Read More
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Managed Care Reflections: A Q&A With David J. Shulkin, MD
July 7th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The July issue features a conversation with David J. Shulkin, MD, a physician and former secretary of the US Department of Veterans Affairs.
Read More